Tamoxifen is a synthetic hormonal antagonist that binds to estrogen receptors in breast tissue. It is primarily used to treat hormone receptor positive breast cancer in both premenopausal and postmenopausal women. By occupying the estrogen receptor, Tamoxifen blocks the activation of signaling pathways that promote cell proliferation. This blockade leads to inhibition of estrogen driven gene expression and reduces tumor growth and metastasis. In addition to its anti-estrogenic effect, Tamoxifen can exhibit partial agonist activity in bone tissue, helping to maintain bone density. Its metabolites, such as endoxifen, increase the drug's potency by further reducing estrogen receptor signaling. Overall the medication alters cellular responses to estrogen, providing therapeutic benefit in estrogen dependent cancers.

Tamoxifen is a selective estrogen receptor modulator used primarily in the treatment of estrogen receptor positive breast cancer. It binds to estrogen receptors in breast tissue and blocks the activation of these receptors by natural estrogen, thereby inhibiting the growth signals that promote tumor progression. In other tissues such as bone and uterus the drug can act as an estrogen agonist, leading to different biological outcomes depending on the cellular context. The medication is metabolized in the liver to active metabolites including endoxifen, which contributes significantly to its anti-estrogenic potency. Its pharmacokinetic profile features a long half-life and variable metabolism among individuals, which can influence therapeutic response. By modulating estrogen signaling, Tamoxifen interferes with the interactions between estrogen and its receptor that are required for cell proliferation and survival. This antagonism reduces transcriptional activation of genes involved in the cell cycle and promotes apoptosis in susceptible cancer cells. Overall the drug's pharmacological action results in decreased estrogen driven tumor growth while maintaining a antagonistic effect in certain tissues.

Tamoxifen may cause hot flashes and night sweats. It can lead to nausea and occasional vomiting. Some patients experience fatigue and mild dizziness. There is a possibility of mild joint pain and muscle stiffness. Rarely it may affect libido and cause changes in menstrual patterns. Long term use can increase the risk of endometrial thickening.

Tamoxifen is a medication commonly used in the treatment of hormone receptor positive breast cancer. Nausea is one of the frequently reported side effects. Hot flashes often occur during treatment. Fatigue can affect daily energy levels. Some patients experience menstrual irregularities or changes in cycle patterns. Weight gain has been observed in certain individuals. Vaginal discharge or dryness may develop as a result of hormonal changes. Bone density loss is a long term concern that requires monitoring.